Comparative effectiveness of hyperthermic intraperitoneal chemotherapy for gastric cancer
A systematic review and network meta-analysis protocol

Zhaolun Cai, MD, Zhaohui Cai, MD, Tao He, MD, Zhou Zhao, MD, Yuan Yin, MD, Chaoyong Shen, MD, Xiaonan Yin, MD, Zhixin Chen, PhD, Cao Dan, PhD, Bo Zhang, PhD.

Abstract
Background: Comparative efficacy and safety of different hyperthermic intraperitoneal chemotherapies (HIPEC) in patients with advanced gastric cancer who underwent gastrectomy is unclear. To investigate this question, we conduct a systematic review and network meta-analysis.

Methods: The protocol followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols. PubMed, Embase, and the Cochrane Library will be searched systematically for eligible randomized controlled trials without language restriction. The primary outcome is overall survival. The second outcomes are postoperative complications. The surface under the cumulative ranking curve value will be calculated to establish a hierarchy of the treatments.

Results: The results will provide useful information about the effectiveness and safety of HIPEC regimens in patients with resected gastric cancer.

Conclusion: The findings of the study will be disseminated through peer-reviewed journal.

Abbreviations: CIs = confidence intervals, HIPEC = hyperthermic intraperitoneal chemotherapy, OR = odds ratio.

Keywords: gastric cancer, hyperthermic intraperitoneal chemotherapy, network meta-analysis

1. Introduction
Stomach cancer is the third leading cause of death from cancer worldwide in 2016.11 Complete surgery remains the major curative treatment for localized gastric cancer.2,11 Even despite potentially curative surgery, the prognosis of the patients with the disease remains poor mainly due to peritoneal recurrence or local recurrence after radical gastrectomy.4–6 Peritoneal recurrence was observed most frequently in recurrent gastric cancer.6 The high risk of peritoneal recurrence prompted the investigation of hyperthermic intraperitoneal chemotherapy (HIPEC) as a therapeutic option, and the efficacy of which has been confirmed by previous studies.7–10 However, there is no established consensus on optimal HIPEC regimens because of the shortage of head-to-head trials and the limitation of traditional pair-wise meta-analyses. As the novel treatments are being developed to improve the survival of patients with advanced gastric cancer, the efficacy and safety of HIPEC regimens require closer and more sophisticated evaluation.

In this study, we will perform a systematic review and network meta-analysis to investigate the comparative effectiveness and safety of enrolled HIPEC regimens in patients with advanced gastric cancer who underwent gastrectomy.

2. Methods
The protocol follows PRISMA-P checklist,11 and the study will follow PRISMA guidelines.12 The systematic review and meta-analysis will be conducted following an established protocol (PROSPERO: CRD42018099451). The study is a meta-analysis of aggregate data which do not involve human subjects and do not need ethical approval.

2.1. Eligibility criteria
The detailed eligibility criteria are summarized using PICOS approach (patients, intervention, comparisons, outcome, and study design type).

2.1.1. Patients and comparison of interventions. We will include studies that contain patients with gastric cancer treated with at least 2 arms of following treatments: surgery with different HIPEC regimens or surgery alone. Studies should...
provide sufficient data of survival rates. There are no restrictions in age, ethnic distribution, and gender.

2.1.2. Outcomes. The primary outcome is overall survival (OS). The second outcome is postoperative morbidity.

2.1.3. Study design. Published RCTs with no language restriction will be included in the meta-analysis.

2.2. Information sources
PubMed, Embase, and the Cochrane library (Jun 2018) will be systematically searched for eligible studies.

2.3. Search strategy
Search strategy of PubMed was as follows:

#1 (((Gastric cancer) OR stomach cancer) OR stomach neoplasm) OR “Gastric cancers”) OR “stomach cancers”) OR “stomach neoplasms”

#2 (intraperitoneal perfusion) OR “peritoneal perfusion”) OR hyperthermic intraperitoneal chemotherapy) OR intraperitoneal chemotherapy

#3 (((Randomized Controlled Trial” [Publication Type]) OR “Controlled Clinical Trial” [Publication Type]) OR “randomized” [tiab]) OR “placebo” [tiab]) OR “Clinical Trials as Topic”[Mesh:NoExp]) OR “randomly” [tiab]) OR “trial” [ti]) NOT ((“Animals” [mh]) NOT “humans” [mh])

#4 #1 AND #2 AND #3

2.4. Study selection and data extraction
Two reviewers will perform study selection and data extraction. The selection process will be summarized in a PRISMA flow diagram (Fig. 1). The data include study characteristics (authors, year of publication, and countries), data needed for quality assessment, and characteristics of patients including intervention, follow-up time, mean age, outcomes and tumor pathologic variables. Hazard ratios (HRs) will be extracted from studies on
the basis of reported values or be estimated from survival curves by established methods.[13] All study characteristics will be summarized in the same standardized collection form by 2 reviewers.

2.5. Risk of bias

The risk of bias of included RCTs will be independently assessed by 2 investigators using the Cochrane Collaboration’s tool for assessing risk of bias in randomized trials,[14] in terms of sequence generation, allocation concealment, blinding of participants and researchers, incomplete outcome data, selective reporting, and other bias random. Disagreements will be resolved in group discussion.

2.6. Data synthesis and statistical analysis

2.6.1. Pairwise meta-analyses. R software version 3.5.0 will be used to perform pairwise meta-analyses. Pooled odds ratio (OR) will be calculated for dichotomous data. Pooled HR will be used to perform pairwise meta-analyses. Pooled OR will be calculated for dichotomous data. Pooled HR will be used to perform pairwise meta-analyses. Pooled odds ratio (OR) will be calculated for time-to-event data.

We will use the same toolkit as the included studies by I^2 statistic. χ^2 test with the significance set P < .10 or 12 > 50% indicates statistical heterogeneity.[15] A fixed effect will be used to calculate the outcomes when statistical heterogeneity is absent, whereas a random-effects model will be used. Publication bias will be assessed by Begg’s funnel plot and Egger regression, if the study includes 10 or more studies.[16,17]

2.6.2. Network meta-analyses. A Bayesian network meta-analysis will be performed with R x64 3.5.0. We will use the node splitting method to assess the inconsistency between direct and indirect comparisons if a loop exists.[18] Surface under the cumulative ranking area (SUCRA) values will be used to rank the different HIPEC regimens.[19] Comparison-adjusted funnel plots will be drawn to detect the small sample effects of on the results. A network plot will be conducted to present the comparisons of the treatment across trials to ensure if a network meta-analysis is feasible. Studies will be excluded if the treatments investigated are not connected by other treatments. All the result figures will be generated using R x64 3.5.0 and STATA version 14.0 (College Station, TX).

3. Discussion

Currently, the optimal HIPEC regimen for resected gastric cancer is still uncertain. Therefore, we conduct a network meta-analysis to investigate the question. To the best of our knowledge, this is the first network meta-analysis in the area. We aim to summarize direct and indirect evidence and provide evidence-based suggestions for the clinical use of HIPEC.

Author contributions

Bo Zhang, Dan Cao and Zhaolun Cai conceived the concept and designed the study protocol. Zhaohui Cai and Tao He tested the feasibility of the study. Zhixin Chen, Chaoyong Shen, Yuan Yin, Xiaoran Yin, and Zhou Zhao wrote the manuscript. Bo Zhang, Dan Cao and Zhaolun Cai provided methodological advice, polished and revised the manuscript. All authors saw and approved the final version of the paper.

Conceptualization: Zhaolun Cai, Cao Dan, Bo Zhang. Investigation: Zhaohui Cai, Tao He. Methodology: Zhaolun Cai, Cao Dan, Bo Zhang. Writing – original draft: Zhou Zhao, Yuan Yin, Chaoyong Shen, Xiaoran Yin, Zhixin Chen. Writing – review & editing: Zhaolun Cai, Cao Dan, Bo Zhang. Zhaolun Cai: 0000-0002-3706-6703

References

[1] Moraga-Serrano PE. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study. JAMA Oncol 2018;doi: 10.1001/jamaoncol.2018.2706.

[2] van Cutsem E, Dirix L, Geva R, et al. The diagnosis and management of gastric cancer: Expert discussion and recommendations from the 12th ESMO World Congress on Gastrointestinal Cancer, Barcelona, 2010. Ann Oncol 2011;22(Suppl 5):v1–9.

[3] Van de Velde CJ, Peeters KC. The gastric cancer treatment controversy. Am Soc Clin Oncol 2003;21:2234–6.

[4] Briasoulis E, Liakakos T, Dova L, et al. Selecting a speciﬁc pre–postoperative adjuvant therapy for individual patients with operable gastric cancer. Expert Rev Anticancer Ther 2006;6:931–9.

[5] Reim D, Loos M, Vogl F, et al. Prognostic implications of the seventh edition of the international union against cancer classiﬁcation for patients with gastric cancer: The Western Experience of Patients Treated in a Single-Center European Institution. J Clin Oncol 2013;31:263–71.

[6] Yoo CH, Noh SH, Shin DW, et al. Recurrence following curative resection for gastric carcinoma. Br J Surg 2000;87:236.

[7] Desiderio J, Chao J, Melstrom L, et al. The 30-year experience: A meta-analysis of randomized and high-quality non-randomized studies of hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer. Eur J Cancer (Oxford, England: 1990) 2013;49:701–4.

[8] Mi DH, Li Z, Yang KH, et al. Surgery combined with intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) for gastric cancer: a systematic review and meta-analysis of randomised controlled trials. Int J Hypertherm 2013;29:156–67.

[9] Sun J, Song Y, Wang Z, et al. Beneﬁts of hyperthermic intraperitoneal chemotherapy for patients with serosal invasion in gastric cancer: a meta-analysis of the randomized controlled trials. BMC Cancer 2012;12:526.

[10] Huang JY, Xu YY, Sun Z, et al. Comparison different methods of intraoperative and intraperitoneal chemotherapy for patients with gastric cancer: a meta-analysis. Asian Pac J Cancer Prev 2012;13:4379–85.

[11] Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:1.

[12] Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 2009;62:e1–34.

[13] Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16.

[14] Higgins JT, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928–30.

[15] Gs HJP. Cochrane handbook for systematic reviews of interventions version 5.1.0 (updated March 2011). Naunyn-Schmiedebergs Archiv Exp Pathol Pharmacol 2014;5:538.

[16] Egger M, Davey SG, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629–34.

[17] Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088–101.

[18] Dias S, Welton NJ, Caldwell DM, et al. Checking consistency in mixed treatment comparison meta-analysis. Stat Med 2010;29:932–44.

[19] Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 2011;64:116–71.